Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Relief Therapeutics Ord Shs RLFTF

Healthcare Biotechnology
RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of... see more

Recent & Breaking News (OTCQB:RLFTF)

Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update

ACCESS Newswire August 30, 2024

Relief Therapeutics Secures up to $11 Million from Royalty Sales

ACCESS Newswire August 5, 2024

RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting

ACCESS Newswire June 27, 2024

Relief Therapeutics Announces Executive Changes

ACCESS Newswire June 3, 2024

Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders

ACCESS Newswire May 30, 2024

Relief Therapeutics Announces New Executive Leadership Team Strengthening Capabilities to Guide the Company through Pipeline Development Initiatives

ACCESS Newswire May 8, 2024

Relief Therapeutics has Published its Annual Report

ACCESS Newswire April 30, 2024

RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting

ACCESS Newswire April 26, 2024

Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE

ACCESS Newswire March 22, 2024

Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria

GlobeNewswire March 22, 2024

Relief Therapeutics Renews CHF 50 million Share Subscription Facility

ACCESS Newswire February 28, 2024

Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth

ACCESS Newswire December 5, 2023

Relief Therapeutics Announces CEO Transition

ACCESS Newswire November 22, 2023

Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone

ACCESS Newswire October 10, 2023

Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update

ACCESS Newswire September 15, 2023

Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

ACCESS Newswire September 1, 2023

Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics

ACCESS Newswire August 30, 2023

Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec Health

ACCESS Newswire July 19, 2023

RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement

ACCESS Newswire June 23, 2023

Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE(R) in the Middle East

ACCESS Newswire June 23, 2023